Ophtec Launches New Brand Identity_Thumbnail

Ophtec Kicks Off 40th Anniversary with New Look

Known for its IOLs, the company sets its sights on the future with an updated brand identity 

Leading premium intraocular lens (IOL) manufacturer Ophtec (Groningen, the Netherlands) is celebrating its 40th anniversary with a new brand identity. Known for developing high quality solutions, this new “look” will elevate the company’s brand to the same high level as its innovative products.

Ophtec was founded in 1983 by Prof. Dr. Jan Worst, a famed Dutch ophthalmologist with the ambition of creating better products than were currently on market, explained CEO Erik Jan Worst. Since then, the family-owned company has proven that this core value remains at the forefront through its premium product development. 

“Ophtec always had a full focus on making unique products. Our people are highly dedicated and we support ophthalmologists so they can do the best job possible,” said Remko Bos, Ophtec’s marketing manager. “Our branding was somehow underexposed … so, this year is a great moment for us to honor our heritage, freshen up our brand, and connect with a new generation of eye doctors,” he added.

According to Bos, the renewed brand is quite a transformation with a new logo and eye-catching colors — but although the look is new, the focus is the same: “We remain Ophtec, a partner to ophthalmologists worldwide, and together, we help people to see clearly.”

Along with the milestone anniversary and rebranding, Ophtec will also celebrate new products and study results in 2023. This includes the South Korean launch of ArtiPlus, a new iris-fixated phakic IOL for presbyopia correction. “In Europe, the clinical study is running and we can already see the results are spectacular,” said Worst. “We’re also introducing a new preloaded injector system for our Precizon cataract lenses … and we expect to launch a new, exciting lens concept after the summer break.”

Check out Ophtec’s new look at www.ophtec.com

Notify of
Inline Feedbacks
View all comments